Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast - Trial NCT06340984
Access comprehensive clinical trial information for NCT06340984 through Pure Global AI's free database. This Phase 3 trial is sponsored by South Valley University and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
South Valley University
Timeline & Enrollment
Phase 3
Jun 01, 2024
Feb 01, 2025
Primary Outcome
Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne vulgaris (moderate -severe ),Montelukast in treatment of acne vulgaris patients
Summary
The aim of this study is to:
 
 1. Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne
 vulgaris and compare it to control group
 
 2. Evaluate its role in acne pathogenesis and its correlation with acne vulgaris severity
 
 3. Evaluate the effect of Montelukast on serum (sICAM-1) level in acne vulgaris
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06340984
Non-Device Trial